BridgeMD
Open-label extension study with filgotinib in children with juvenile idiopathic arthritis.
EU CTIS ID: 2025-523239-21-00
What this study is testing
To determine the long-term safety and tolerability of filgotinib in children and adolescents who completed the parent studies of filgotinib in pJIA and sJIA.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject must have completed treatment with filgotinib in at least one parent study (GLPG0634-CL-131, GLPG0634-CL-329, or GLPG0634-CL-328) and achieved a clinical benefit at the end of the parent protocols.
- Subject and/or parent/legal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the informed consent form and assent (if required per local regulation) as approved by the Independent Ethics Committee/Institutional Review Board, prior to any protocol evaluations.
- Female or male subject 8 to <18 years of age, on the date of signing the informed consent and assent (per local regulation) form.
- Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception/preventive exposure measures as described in the clinical study protocol.
You likely can't join if
- Development of any condition during the parent study that would preclude safe continuation.
- Pregnancy.
- Active infection that is clinically significant, as per Investigator’s judgment.
- Subject with known hypersensitivity to the components of potential study therapy.
- Subjects with any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.